Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiov...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 01:16:36 23 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 01:16:36 23 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/23/2009 1:18:08 PM

RSS FEED

» Help

Current DateTime: 01:16:37 23 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Jul.01
10:33 AM ET
Tuesday, 1 Jul 2008
Abbott, Boston Scientific Stents & Stuff

Heart Stent
Rick Lee
Heart Stent

So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott [ABT  Loading...      ()   ]drug-coated stent will not happen in the second quarter.

Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4. The question now is whether the FDA will make a move before the July 4th holiday. Any bets?

Speaking of stents, a folo-up to my post last week on the analyst report saying that Boston Scientific [BSX  Loading...      ()   ]is discounting its drug-coated stent when they're bought along with other medical devices the company makes. At first, a BSX spokesman told me the company doesn't publicly talk about such alleged deals. But then Paul Donovan sent me another email last night asking in the subject line, "What were you smoking?" He took me to task for repeating "an unsubstantiated claim we're (BSX) selling stents for $1,100. We sell stents for about double that, and often more."

And as long as we're on the subject of corporate communications I wanted to pass along this anecdote about yesterday's Alzheimer's drug news out of Myriad Genetics[MYGN  Loading...      ()   ]. My producer, Ruth, had been working with their people to make sure we were in the loop when the biotech company released the highly anticipated late-stage test results. But the relationship-building groundwork was all for naught.

The press release went out before the opening bell on Monday, but we got no heads up or even an email once the release went out to make sure we saw it. I was out of pocket on assignment in Washington, DC, but reachable--as always--via BlackBerry. When Ruth queried the MYGN point-person about the oversight he replied, "We were planning personal outreach to you on positive results. Then when we found out the results were negative, no one thought to make sure you were on the email distribution list."

Oh, and I wasn't smoking anything when I wrote the BSX post. Aside from what I think was a contact high during my freshman year in the USC Trojan Marching Band on a bus returning from a gig, I've never inhaled.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 01:14:12 23 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 10:08:23 23 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 10:23:55 23 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:08:15 23 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters